Jayne, David R Steffgen, Jürgen Romero-Diaz, Juanita Bajema, Ingeborg Boumpas, Dimitrios T Noppakun, Kajohnsak Amano, Hirofumi Gomez, Harold Michael Satirapoj, Bancha Avihingsanon, Yingyos
...
Funder: Boehringer Ingelheim; doi: http://dx.doi.org/10.13039/100001003 / Funder: NIHR Cambridge Biomedical Research Centre; doi: http://dx.doi.org/10.13039/501100018956 / OBJECTIVE: To characterize its dose-response relationship, BI 655064 (an anti-CD40 monoclonal antibody) was tested as an add-on to mycophenolate and glucocorticoids in patients w...
McClure, Mark E Gopaluni, Seerapani Wason, James Henderson, Robert B Van Maurik, Andre Savage, Caroline CO Pusey, Charles D Salama, Alan D Lyons, Paul A Lee, Jacinta
...
BACKGROUND: Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms. METHODS: Study design: COMBIVAS is a randomised, double-blind, placebo-controlled trial designed to assess the mechanistic effects of sequ...
Liu, Wei Yu, Zhiheng Wang, Ziyu Waubant, Emmanuelle L Zhai, Suodi Benet, Leslie Z
The objective of this study was to determine the potential usefulness of an animal model to predict the appropriate dose of newly developed drugs for treating relapsing remitting multiple sclerosis (RRMS). Conversion of the lowest effective dose (LEffD) for mice and rats in the experimental autoimmune encephalomyelitis (EAE) model was used to predi...
Louis, Edouard Resche-Rigon, Matthieu Laharie, David Satsangi, Jack Ding, Nik Siegmund, Britta D'Haens, Geert Picon, Laurence Bossuyt, Peter Vuitton, Lucine
...
peer reviewed / BACKGROUND: The combination of infliximab and immunosuppressant therapy is a standard management strategy for patients with Crohn's disease. Concerns regarding the implications of long-term combination therapy provided the rationale for a formal clinical trial of treatment de-escalation. Our aim was to compare the relapse rate and t...
Isnardi, Carolina Ayelen Soriano, Enrique R Graf, Cesar de la Vega, María Celina Pons-Estel, Bernardo A Roberts, Karen Quintana, Rosana Gomez, Gimena Yazdany, Jinoos Saurit, Verónica
...
Background/objectiveThis study describes the impact of immunomodulatory and/or immunosuppressive (IM/IS) drugs in the outcomes of COVID-19 infection in a cohort of patients with immune-mediated inflammatory diseases (IMIDs).MethodsAdult patients with IMIDs with a confirmed SARS-CoV-2 infection were included. Data were reported by the treating physi...
Peyrin-Biroulet, Laurent Rahier, Jean-François Kirchgesner, Julien Abitbol, Vered Shaji, Sebastian Armuzzi, Alessandro Karmiris, Konstantinos Gisbert, Javier P Bossuyt, Peter Helwig, Ulf
...
peer reviewed / BACKGROUND AND AIMS: There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary objective of I-CARE (IBD Cancer and serious infections in Europe) was to assess prospectively safety concerns in IBD, with specific focus on the ri...
Wood-Trageser, Michelle Lesniak, Drew Gambella, Alessandro Gambella, Alessandro Golnoski, Kayla Feng, Sandy Bucuvalas, John Sanchez-Fueyo, Alberto Demetris, A
BACKGROUND AND AIMS: In otherwise near-normal appearing biopsies by routine light microscopy, next-generation pathology (NGP) detected close pairings (immune pairs; iPAIRs) between lymphocytes and antigen-presenting cells (APCs) that predicted immunosuppression weaning failure in pediatric liver transplant (LTx) recipients (Immunosuppression Withdr...
Bruera, Sebastian Lei, Xiudong Zhao, Hui Yazdany, Jinoos Chavez-MacGregor, Mariana Giordano, Sharon H Suarez-Almazor, Maria E
ObjectivesWe compared the outcomes of patients with or without systemic lupus erythematosus (SLE) who were diagnosed with coronavirus disease 19 (COVID-19) and evaluated factors within patients with SLE associated with severe outcomes.MethodsThis retrospective cohort study used the deidentified Optum COVID-19 electronic health record dataset to ide...
Smith, Rona M Jones, Rachel B Specks, Ulrich Bond, Simon Nodale, Marianna Al-Jayyousi, Reem Andrews, Jacqueline Bruchfeld, Annette Camilleri, Brian Carette, Simon
...
Peer reviewed: True / Acknowledgements: The RITAZAREM trial is directed by the European Vasculitis Society and the Vasculitis Clinical Research Consortium (VCRC). The primary sponsor is Cambridge University Hospitals NHS Foundation Trust, and there are collaboration and data-sharing agreements with the University of Pennsylvania and the University ...
Rahaghi, Franck Hsu, Vivien Kaner, Robert Mayes, Maureen Rosas, Ivan Saggar, Rajan Steen, Virginia Strek, Mary Bernstein, Elana Bhatt, Nitin
...
BACKGROUND: Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial lung disease (ILD) is common in SSc, occurring in 35-52% of patients and accounting for 20-40% of mortality. Evolution of therapeutic options has resulted in a lack of consensus on how to manage this condition. This Delphi study was initiated to develo...